Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 5Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 2

Conditions

Melanoma 23Neoplasm Metastasis 11Leukemia, Myeloid, Acute 11Pancreatic Neoplasms 7Ovarian Neoplasms 7Carcinoma, Renal Cell 7Leukemia 6Kidney Neoplasms 6Breast Neoplasms 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Lymphoma 5Carcinoma, Non-Small-Cell Lung 5Neuroblastoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Colonic Neoplasms 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia, Myelomonocytic, Chronic 3Gastrointestinal Neoplasms 3Congenital Abnormalities 3Vulvar Neoplasms 2Vaginal Neoplasms 2Uveal Melanoma 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2

Interventions

Dexamethasone 132Lenalidomide 58Bortezomib 56Calcium Dobesilate 44Melphalan 41carfilzomib 38pomalidomide 36Cyclophosphamide 35daratumumab 23belantamab mafodotin 21Peripheral Blood Stem Cell Transplantation 17ixazomib 16dexamethasone acetate 13Filgrastim 13Bendamustine Hydrochloride 13fludarabine phosphate 12fludarabine 12dexamethasone 21-phosphate 12Tacrolimus 12auricularum 11Whole-Body Irradiation 11liposomal doxorubicin 10iberdomide 10Prednisone 10venetoclax 9selinexor 9isatuximab 9Mycophenolic Acid 9pembrolizumab 8Cyclosporine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Multiple Myeloma × aldesleukin × Clear all
NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Indapta Therapeutics, INC.

Phase 1/2 Recruiting
128 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

NCT00248430 2010-09-21

Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Completed
20 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡